Dateline City:
WHITEHOUSE STATION, N.J.
New Research Initiative Seeks to Identify Unmet Needs and Address Key Gaps in the Management of Type 2 Diabetes
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the launch of a global registry to evaluate the
experiences and outcomes of approximately 20,000 patients with type 2
diabetes in real-world settings over three years. The registry is part
of Mercks new global research initiative evaluating outcomes of
patients with type 2 diabetes in everyday clinical practice.
Language:
English
Contact:
Media:Pam Eisele267-305-3558orKim Hamilton908-423-6831 / 908-391-0131orInvestors:Justin Holko908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more